These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24751813)

  • 1. Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment.
    Drago A; Giegling I; Schäfer M; Hartmann AM; Konte B; Friedl M; Serretti A; Rujescu D
    Pharmacogenet Genomics; 2014 Jun; 24(6):314-9. PubMed ID: 24751813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics.
    Schuhmacher A; Becker T; Rujescu D; Quednow BB; Lennertz L; Wagner M; Benninghoff J; Rietschel M; Häfner H; Franke P; Wölwer W; Gaebel W; Maier W; Mössner R
    J Psychiatr Res; 2012 Aug; 46(8):1073-80. PubMed ID: 22655589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
    Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia.
    Greenbaum L; Alkelai A; Rigbi A; Kohn Y; Lerer B
    Mov Disord; 2010 Dec; 25(16):2809-17. PubMed ID: 20939080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients.
    Spellmann I; Rujescu D; Musil R; Meyerwas S; Giegling I; Genius J; Zill P; Dehning S; Cerovecki A; Seemüller F; Schennach R; Hartmann AM; Schäfer M; Müller N; Möller HJ; Riedel M
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jun; 51():190-5. PubMed ID: 24576533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment.
    Drago A; Giegling I; Schäfer M; Hartmann AM; Friedl M; Konte B; Möller HJ; De Ronchi D; Stassen HH; Serretti A; Rujescu D
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):887-94. PubMed ID: 22980146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients.
    Spellmann I; Rujescu D; Musil R; Mayr A; Giegling I; Genius J; Zill P; Dehning S; Opgen-Rhein M; Cerovecki A; Hartmann AM; Schäfer M; Bondy B; Müller N; Möller HJ; Riedel M
    J Psychiatr Res; 2011 Feb; 45(2):234-41. PubMed ID: 20598711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia.
    Crisafulli C; Chiesa A; De Ronchi D; Han C; Lee SJ; Park MH; Patkar AA; Pae CU; Serretti A
    Neurosci Lett; 2012 Jan; 506(1):170-4. PubMed ID: 22094384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study.
    Yu H; Yan H; Wang L; Li J; Tan L; Deng W; Chen Q; Yang G; Zhang F; Lu T; Yang J; Li K; Lv L; Tan Q; Zhang H; Xiao X; Li M; Ma X; Yang F; Li L; Wang C; Li T; Zhang D; Yue W;
    Lancet Psychiatry; 2018 Apr; 5(4):327-338. PubMed ID: 29503163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
    Yen YC; Lung FW; Chong MY
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
    Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment.
    Gupta M; Bhatnagar P; Grover S; Kaur H; Baghel R; Bhasin Y; Chauhan C; Verma B; Manduva V; Mukherjee O; Purushottam M; Sharma A; Jain S; Brahmachari SK; Kukreti R
    Pharmacogenomics; 2009 Mar; 10(3):385-97. PubMed ID: 19290789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.
    Müller DJ; Klempan TA; De Luca V; Sicard T; Volavka J; Czobor P; Sheitman BB; Lindenmayer JP; Citrome L; McEvoy JP; Lieberman JA; Honer WG; Kennedy JL
    Neurosci Lett; 2005 May; 379(2):81-9. PubMed ID: 15823421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects.
    Giegling I; Drago A; Schäfer M; Möller HJ; Rujescu D; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):74-7. PubMed ID: 20868720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.
    Giegling I; Balzarro B; Porcelli S; Schäfer M; Hartmann AM; Friedl M; Konte B; Krämer P; Möller HJ; De Ronchi D; Stassen HH; Serretti A; Rujescu D
    Eur Arch Psychiatry Clin Neurosci; 2013 Feb; 263(1):65-74. PubMed ID: 22893251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Huang CH; Tsai GE
    J Clin Psychopharmacol; 2008 Feb; 28(1):64-8. PubMed ID: 18204343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.